Dr. Reddys Laboratories Ltd.

Dr. Reddy’s Laboratories is currently trading at Rs. 2791.35, up by 17.45 points or 0.63% from its previous closing of Rs. 2773.90 on the BSE.

The scrip opened at Rs. 2785.90 and has touched a high and low of Rs. 2799.00 and Rs. 2785.90 respectively. So far 1124 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 2815.00 on 24-Feb-2014 and a 52 week low of Rs. 1720.50 on 01-Mar-2013.

Last one week high and low of the scrip stood at Rs. 2815.00 and Rs. 2650.00 respectively. The current market cap of the company is Rs. 47,474.00 crore.

The promoters holding in the company stood at 25.52% while Institutions and Non-Institutions held 40.90% and 16.48% respectively. Dr. Reddy’s Laboratories has launched Sumatriptan Injection USP, Autoinjector System 6 mg/0.5 ml, for Subcutaneous Use, a therapeutic equivalent generic version of IMITREX STATdose Pen (sumatriptan succinate) 6 mg/0.5 ml in the US market on February 25, 2014, following the approval by the United States Food & Drug Administration (USFDA). Dr. Reddy’s Sumatriptan Injection USP, Autoinjector System 6 mg/ 0.5 ml is available in a carton containing 2 single-dose prefilled syringes.

The IMITREX STATdose Pen (sumatriptan succinate) brand and generic combined had US sales of approximately $169 Million MAT for the most recent twelve months ending in December 2013 according to IMS Health.

Dr. Reddy’s is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.